Serious fungal infections in Egypt
We aimed to estimate the burden of serious fungal infections in Egypt, currently unknown, based on the size of the populations at risk and available epidemiological data. Data were obtained from the World Health Organization (WHO), the Joint United Nations Programme on HIV/AIDS (UNAIDS), and publish...
Gespeichert in:
| Veröffentlicht in: | European journal of clinical microbiology & infectious diseases 2017-06, Vol.36 (6), p.971-974 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 974 |
|---|---|
| container_issue | 6 |
| container_start_page | 971 |
| container_title | European journal of clinical microbiology & infectious diseases |
| container_volume | 36 |
| creator | Zaki, S. M. Denning, D. W. |
| description | We aimed to estimate the burden of serious fungal infections in Egypt, currently unknown, based on the size of the populations at risk and available epidemiological data. Data were obtained from the World Health Organization (WHO), the Joint United Nations Programme on HIV/AIDS (UNAIDS), and published reports with clearcut denominators. When no data existed, risk populations were used to estimate frequencies of fungal infections, using previously described methodology. The population of Egypt in 2011 was ∼82,500,000; 31% children, and 8% women >60 years of age. Amongst about 21.8 million women aged 15–50 years, recurrent vulvovaginal candidiasis (≥4 episodes/year) is estimated to occur in 1.3 million (3,169/100,000 females). Using a low international average rate of 5/100,000, we estimate 4,127 cases of candidaemia, and 619 patients with intra-abdominal candidiasis. Amongst the survivors of pulmonary tuberculosis (TB) in Egypt in 2012, 319 new cases of chronic pulmonary aspergillosis (CPA) are likely, a prevalence of 1,005 post-TB and a total prevalence estimate of 3,015 CPA patients in all. Asthma is common in Egypt, affecting 9.4% of adults, 5.35 million, and so ABPA and SAFS were estimated in around 162/100,000 and 214/100,000 respectively. Invasive aspergillosis is estimated to affect 495 patients following leukaemia therapy, there are an estimated 37 cases in renal and liver transplant recipients, and an estimated 132 patients develop IA in the context of lung cancer. Amongst 641,000 COPD admissions to hospital each year, 8,337 patients develop IA. The total HIV-infected population is small, with an estimated 6,500 patients, 2,500 not on antiretroviral therapy. Amongst HIV-infected patients, 38 (0.6%) cases of cryptococcal meningitis and 125 (1.9%) cases of
Pneumocystis
pneumonia are estimated each year. Fungal keratitis is common, with 28–55% (mean 40%) of corneal infections being fungal, an estimated total of 11,550 cases. The present study indicates that 2% of the Egyptian population is affected by fungal infections. The estimates are certainly incomplete, and need further epidemiological and diagnostic studies. |
| doi_str_mv | 10.1007/s10096-017-2929-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1869966069</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1869966069</sourcerecordid><originalsourceid>FETCH-LOGICAL-c415t-cf31f8c2ea25d32e67af97715c3183d5337f61b8909521900ae28671ba665fa53</originalsourceid><addsrcrecordid>eNp1kE1LAzEURYMotlZ_gBspunETzct3llLqBxRcqOuQmSZlynSmJjOL_ntTpooIbpJAzr3vcRC6BHIHhKj7lE8jMQGFqaEG8yM0Bs4E5kyxYzQmhnFsFGUjdJbSmuSMVuoUjaimwKQ2Y3T95mPV9mka-mbl6mnVBF92Vduk_JzOV7ttd45OgquTvzjcE_TxOH-fPePF69PL7GGBSw6iw2VgEHRJvaNiyaiXygWjFIiSgWZLwZgKEgptiBEUDCHOUy0VFE5KEZxgE3Q79G5j-9n71NlNlUpf167xeUMLWhojJZEmozd_0HXbxyZvZ3MzSE4E05mCgSpjm1L0wW5jtXFxZ4HYvUA7CLRZoN0LtDxnrg7NfbHxy5_Et7EM0AFI-atZ-fhr9L-tXxj2d-A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1901640538</pqid></control><display><type>article</type><title>Serious fungal infections in Egypt</title><source>MEDLINE</source><source>SpringerLink</source><creator>Zaki, S. M. ; Denning, D. W.</creator><creatorcontrib>Zaki, S. M. ; Denning, D. W.</creatorcontrib><description>We aimed to estimate the burden of serious fungal infections in Egypt, currently unknown, based on the size of the populations at risk and available epidemiological data. Data were obtained from the World Health Organization (WHO), the Joint United Nations Programme on HIV/AIDS (UNAIDS), and published reports with clearcut denominators. When no data existed, risk populations were used to estimate frequencies of fungal infections, using previously described methodology. The population of Egypt in 2011 was ∼82,500,000; 31% children, and 8% women >60 years of age. Amongst about 21.8 million women aged 15–50 years, recurrent vulvovaginal candidiasis (≥4 episodes/year) is estimated to occur in 1.3 million (3,169/100,000 females). Using a low international average rate of 5/100,000, we estimate 4,127 cases of candidaemia, and 619 patients with intra-abdominal candidiasis. Amongst the survivors of pulmonary tuberculosis (TB) in Egypt in 2012, 319 new cases of chronic pulmonary aspergillosis (CPA) are likely, a prevalence of 1,005 post-TB and a total prevalence estimate of 3,015 CPA patients in all. Asthma is common in Egypt, affecting 9.4% of adults, 5.35 million, and so ABPA and SAFS were estimated in around 162/100,000 and 214/100,000 respectively. Invasive aspergillosis is estimated to affect 495 patients following leukaemia therapy, there are an estimated 37 cases in renal and liver transplant recipients, and an estimated 132 patients develop IA in the context of lung cancer. Amongst 641,000 COPD admissions to hospital each year, 8,337 patients develop IA. The total HIV-infected population is small, with an estimated 6,500 patients, 2,500 not on antiretroviral therapy. Amongst HIV-infected patients, 38 (0.6%) cases of cryptococcal meningitis and 125 (1.9%) cases of
Pneumocystis
pneumonia are estimated each year. Fungal keratitis is common, with 28–55% (mean 40%) of corneal infections being fungal, an estimated total of 11,550 cases. The present study indicates that 2% of the Egyptian population is affected by fungal infections. The estimates are certainly incomplete, and need further epidemiological and diagnostic studies.</description><identifier>ISSN: 0934-9723</identifier><identifier>EISSN: 1435-4373</identifier><identifier>DOI: 10.1007/s10096-017-2929-4</identifier><identifier>PMID: 28213689</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Acquired immune deficiency syndrome ; Adolescent ; Adult ; Adults ; Aged ; Aged, 80 and over ; AIDS ; Antiretroviral agents ; Antiretroviral therapy ; Aspergillosis ; Asthma ; Biomedical and Life Sciences ; Biomedicine ; Candidemia ; Candidiasis ; Child ; Child, Preschool ; Children ; Chronic obstructive pulmonary disease ; Comorbidity ; Cornea ; Diagnostic systems ; Egypt - epidemiology ; Epidemiology ; Female ; Fungal infections ; Fungi ; Global Fungal Disease Burden ; HIV ; Human immunodeficiency virus ; Humans ; Infant ; Infant, Newborn ; Internal Medicine ; Invasiveness ; Keratitis ; Leukemia ; Liver ; Liver transplantation ; Lung cancer ; Male ; Medical Microbiology ; Meningitis ; Middle Aged ; Mycoses - epidemiology ; Mycoses - pathology ; Original Article ; Patients ; Populations ; Prevalence ; Therapy ; Tuberculosis ; Young Adult</subject><ispartof>European journal of clinical microbiology & infectious diseases, 2017-06, Vol.36 (6), p.971-974</ispartof><rights>Springer-Verlag Berlin Heidelberg 2017</rights><rights>European Journal of Clinical Microbiology & Infectious Diseases is a copyright of Springer, 2017.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c415t-cf31f8c2ea25d32e67af97715c3183d5337f61b8909521900ae28671ba665fa53</citedby><cites>FETCH-LOGICAL-c415t-cf31f8c2ea25d32e67af97715c3183d5337f61b8909521900ae28671ba665fa53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10096-017-2929-4$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10096-017-2929-4$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28213689$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zaki, S. M.</creatorcontrib><creatorcontrib>Denning, D. W.</creatorcontrib><title>Serious fungal infections in Egypt</title><title>European journal of clinical microbiology & infectious diseases</title><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><description>We aimed to estimate the burden of serious fungal infections in Egypt, currently unknown, based on the size of the populations at risk and available epidemiological data. Data were obtained from the World Health Organization (WHO), the Joint United Nations Programme on HIV/AIDS (UNAIDS), and published reports with clearcut denominators. When no data existed, risk populations were used to estimate frequencies of fungal infections, using previously described methodology. The population of Egypt in 2011 was ∼82,500,000; 31% children, and 8% women >60 years of age. Amongst about 21.8 million women aged 15–50 years, recurrent vulvovaginal candidiasis (≥4 episodes/year) is estimated to occur in 1.3 million (3,169/100,000 females). Using a low international average rate of 5/100,000, we estimate 4,127 cases of candidaemia, and 619 patients with intra-abdominal candidiasis. Amongst the survivors of pulmonary tuberculosis (TB) in Egypt in 2012, 319 new cases of chronic pulmonary aspergillosis (CPA) are likely, a prevalence of 1,005 post-TB and a total prevalence estimate of 3,015 CPA patients in all. Asthma is common in Egypt, affecting 9.4% of adults, 5.35 million, and so ABPA and SAFS were estimated in around 162/100,000 and 214/100,000 respectively. Invasive aspergillosis is estimated to affect 495 patients following leukaemia therapy, there are an estimated 37 cases in renal and liver transplant recipients, and an estimated 132 patients develop IA in the context of lung cancer. Amongst 641,000 COPD admissions to hospital each year, 8,337 patients develop IA. The total HIV-infected population is small, with an estimated 6,500 patients, 2,500 not on antiretroviral therapy. Amongst HIV-infected patients, 38 (0.6%) cases of cryptococcal meningitis and 125 (1.9%) cases of
Pneumocystis
pneumonia are estimated each year. Fungal keratitis is common, with 28–55% (mean 40%) of corneal infections being fungal, an estimated total of 11,550 cases. The present study indicates that 2% of the Egyptian population is affected by fungal infections. The estimates are certainly incomplete, and need further epidemiological and diagnostic studies.</description><subject>Acquired immune deficiency syndrome</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Adults</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>AIDS</subject><subject>Antiretroviral agents</subject><subject>Antiretroviral therapy</subject><subject>Aspergillosis</subject><subject>Asthma</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Candidemia</subject><subject>Candidiasis</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>Chronic obstructive pulmonary disease</subject><subject>Comorbidity</subject><subject>Cornea</subject><subject>Diagnostic systems</subject><subject>Egypt - epidemiology</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Fungal infections</subject><subject>Fungi</subject><subject>Global Fungal Disease Burden</subject><subject>HIV</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Internal Medicine</subject><subject>Invasiveness</subject><subject>Keratitis</subject><subject>Leukemia</subject><subject>Liver</subject><subject>Liver transplantation</subject><subject>Lung cancer</subject><subject>Male</subject><subject>Medical Microbiology</subject><subject>Meningitis</subject><subject>Middle Aged</subject><subject>Mycoses - epidemiology</subject><subject>Mycoses - pathology</subject><subject>Original Article</subject><subject>Patients</subject><subject>Populations</subject><subject>Prevalence</subject><subject>Therapy</subject><subject>Tuberculosis</subject><subject>Young Adult</subject><issn>0934-9723</issn><issn>1435-4373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kE1LAzEURYMotlZ_gBspunETzct3llLqBxRcqOuQmSZlynSmJjOL_ntTpooIbpJAzr3vcRC6BHIHhKj7lE8jMQGFqaEG8yM0Bs4E5kyxYzQmhnFsFGUjdJbSmuSMVuoUjaimwKQ2Y3T95mPV9mka-mbl6mnVBF92Vduk_JzOV7ttd45OgquTvzjcE_TxOH-fPePF69PL7GGBSw6iw2VgEHRJvaNiyaiXygWjFIiSgWZLwZgKEgptiBEUDCHOUy0VFE5KEZxgE3Q79G5j-9n71NlNlUpf167xeUMLWhojJZEmozd_0HXbxyZvZ3MzSE4E05mCgSpjm1L0wW5jtXFxZ4HYvUA7CLRZoN0LtDxnrg7NfbHxy5_Et7EM0AFI-atZ-fhr9L-tXxj2d-A</recordid><startdate>20170601</startdate><enddate>20170601</enddate><creator>Zaki, S. M.</creator><creator>Denning, D. W.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20170601</creationdate><title>Serious fungal infections in Egypt</title><author>Zaki, S. M. ; Denning, D. W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c415t-cf31f8c2ea25d32e67af97715c3183d5337f61b8909521900ae28671ba665fa53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Acquired immune deficiency syndrome</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Adults</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>AIDS</topic><topic>Antiretroviral agents</topic><topic>Antiretroviral therapy</topic><topic>Aspergillosis</topic><topic>Asthma</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Candidemia</topic><topic>Candidiasis</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>Chronic obstructive pulmonary disease</topic><topic>Comorbidity</topic><topic>Cornea</topic><topic>Diagnostic systems</topic><topic>Egypt - epidemiology</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Fungal infections</topic><topic>Fungi</topic><topic>Global Fungal Disease Burden</topic><topic>HIV</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Internal Medicine</topic><topic>Invasiveness</topic><topic>Keratitis</topic><topic>Leukemia</topic><topic>Liver</topic><topic>Liver transplantation</topic><topic>Lung cancer</topic><topic>Male</topic><topic>Medical Microbiology</topic><topic>Meningitis</topic><topic>Middle Aged</topic><topic>Mycoses - epidemiology</topic><topic>Mycoses - pathology</topic><topic>Original Article</topic><topic>Patients</topic><topic>Populations</topic><topic>Prevalence</topic><topic>Therapy</topic><topic>Tuberculosis</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zaki, S. M.</creatorcontrib><creatorcontrib>Denning, D. W.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of clinical microbiology & infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zaki, S. M.</au><au>Denning, D. W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serious fungal infections in Egypt</atitle><jtitle>European journal of clinical microbiology & infectious diseases</jtitle><stitle>Eur J Clin Microbiol Infect Dis</stitle><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><date>2017-06-01</date><risdate>2017</risdate><volume>36</volume><issue>6</issue><spage>971</spage><epage>974</epage><pages>971-974</pages><issn>0934-9723</issn><eissn>1435-4373</eissn><abstract>We aimed to estimate the burden of serious fungal infections in Egypt, currently unknown, based on the size of the populations at risk and available epidemiological data. Data were obtained from the World Health Organization (WHO), the Joint United Nations Programme on HIV/AIDS (UNAIDS), and published reports with clearcut denominators. When no data existed, risk populations were used to estimate frequencies of fungal infections, using previously described methodology. The population of Egypt in 2011 was ∼82,500,000; 31% children, and 8% women >60 years of age. Amongst about 21.8 million women aged 15–50 years, recurrent vulvovaginal candidiasis (≥4 episodes/year) is estimated to occur in 1.3 million (3,169/100,000 females). Using a low international average rate of 5/100,000, we estimate 4,127 cases of candidaemia, and 619 patients with intra-abdominal candidiasis. Amongst the survivors of pulmonary tuberculosis (TB) in Egypt in 2012, 319 new cases of chronic pulmonary aspergillosis (CPA) are likely, a prevalence of 1,005 post-TB and a total prevalence estimate of 3,015 CPA patients in all. Asthma is common in Egypt, affecting 9.4% of adults, 5.35 million, and so ABPA and SAFS were estimated in around 162/100,000 and 214/100,000 respectively. Invasive aspergillosis is estimated to affect 495 patients following leukaemia therapy, there are an estimated 37 cases in renal and liver transplant recipients, and an estimated 132 patients develop IA in the context of lung cancer. Amongst 641,000 COPD admissions to hospital each year, 8,337 patients develop IA. The total HIV-infected population is small, with an estimated 6,500 patients, 2,500 not on antiretroviral therapy. Amongst HIV-infected patients, 38 (0.6%) cases of cryptococcal meningitis and 125 (1.9%) cases of
Pneumocystis
pneumonia are estimated each year. Fungal keratitis is common, with 28–55% (mean 40%) of corneal infections being fungal, an estimated total of 11,550 cases. The present study indicates that 2% of the Egyptian population is affected by fungal infections. The estimates are certainly incomplete, and need further epidemiological and diagnostic studies.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>28213689</pmid><doi>10.1007/s10096-017-2929-4</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0934-9723 |
| ispartof | European journal of clinical microbiology & infectious diseases, 2017-06, Vol.36 (6), p.971-974 |
| issn | 0934-9723 1435-4373 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1869966069 |
| source | MEDLINE; SpringerLink |
| subjects | Acquired immune deficiency syndrome Adolescent Adult Adults Aged Aged, 80 and over AIDS Antiretroviral agents Antiretroviral therapy Aspergillosis Asthma Biomedical and Life Sciences Biomedicine Candidemia Candidiasis Child Child, Preschool Children Chronic obstructive pulmonary disease Comorbidity Cornea Diagnostic systems Egypt - epidemiology Epidemiology Female Fungal infections Fungi Global Fungal Disease Burden HIV Human immunodeficiency virus Humans Infant Infant, Newborn Internal Medicine Invasiveness Keratitis Leukemia Liver Liver transplantation Lung cancer Male Medical Microbiology Meningitis Middle Aged Mycoses - epidemiology Mycoses - pathology Original Article Patients Populations Prevalence Therapy Tuberculosis Young Adult |
| title | Serious fungal infections in Egypt |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T13%3A46%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serious%20fungal%20infections%20in%20Egypt&rft.jtitle=European%20journal%20of%20clinical%20microbiology%20&%20infectious%20diseases&rft.au=Zaki,%20S.%20M.&rft.date=2017-06-01&rft.volume=36&rft.issue=6&rft.spage=971&rft.epage=974&rft.pages=971-974&rft.issn=0934-9723&rft.eissn=1435-4373&rft_id=info:doi/10.1007/s10096-017-2929-4&rft_dat=%3Cproquest_cross%3E1869966069%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1901640538&rft_id=info:pmid/28213689&rfr_iscdi=true |